Therapeutic area intelligence for BCL-2 Inhibitor with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

AbbVie →

Assets

BEQALZI →

FDA →

VENCLEXTA →

Recent signals(3)

RegulatoryJuly 19, 2026

FDA Accepts Supplemental NDA for VENCLEXTA by AbbVie

The FDA has accepted a supplemental NDA for VENCLEXTA (venetoclax) from AbbVie.

StrategyJuly 18, 2026

FDA Grants Approval for Dr. Reddy's Venetoclax ANDA214733

The FDA has granted approval for Dr. Reddy's Abbreviated New Drug Application (ANDA) for Venetoclax.

RegulatoryJuly 16, 2026

FDA Grants Priority Review for BEQALZI (Sonrotoclax) NDA220711

The FDA has granted priority review status for BEQALZI, a novel therapy containing sonrotoclax, submitted by Beone Medicines USA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.